Solid dispersions comprising sGC stimulator
The present invention relates to solid dispersions of amorphous 1,1,1,3,3,3-hexafluoro-2-(((5-fluoro-2-(1-(2-fluorobenzyl)-5-(isoxazol-3-yl)-1H-pyrazol-3-yl)pyrimidin-4-yl)amino)methyl)propan-2-ol (Compound I) or a pharmaceutically acceptable salt thereof. It also relates to pharmaceutical compositi...
Saved in:
Main Authors | , , |
---|---|
Format | Patent |
Language | Chinese English |
Published |
23.11.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention relates to solid dispersions of amorphous 1,1,1,3,3,3-hexafluoro-2-(((5-fluoro-2-(1-(2-fluorobenzyl)-5-(isoxazol-3-yl)-1H-pyrazol-3-yl)pyrimidin-4-yl)amino)methyl)propan-2-ol (Compound I) or a pharmaceutically acceptable salt thereof. It also relates to pharmaceutical compositions and pharmaceutical oral dosage unit forms comprising them, and their uses thereof.
本发明涉及无定形1,1,1,3,3,3-六氟-2-(((5-氟-2-(1-(2-氟苄基)-5-(异噁唑-3-基)-1H-吡唑-3-基)嘧啶-4-基)氨基)甲基)丙-2-醇(化合物I)的固体分散体或其药学上可接受的盐。它还涉及包含它们的药物组合物和药物口服剂量单位形式及其用途。 |
---|---|
Bibliography: | Application Number: CN201680077389 |